Price$123.23+0.33 (+0.27%)
01:30 PM07:45 PM
News · 26 weeks66-8%
2025-12-142026-06-07
Mix3890d
- Insider16(42%)
- Other13(34%)
- SEC Filings6(16%)
- Analyst2(5%)
- Leadership1(3%)
Latest news
25 items- SECSEC Form SC TO-C filed by Nuvalent Inc.SC TO-C - Nuvalent, Inc. (0001861560) (Subject)
- SECSEC Form SC14D9C filed by Nuvalent Inc.SC14D9C - Nuvalent, Inc. (0001861560) (Subject)
- PRCancer's Toughest Targets Are Drawing Wall Street's Attention as Oncology Innovation AcceleratesDENVER, June 09, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Artificial intelligence continues to dominate healthcare headlines, but another transformative story is quietly unfolding across biotechnology: the race to develop more effective treatments for some of the deadliest forms of cancer. From precision oncology and targeted therapies to next-generation approaches designed to overcome treatment resistance, a new wave of innovation is emerging that could reshape cancer care over the next decade. One area drawing increasing attention is neuro-oncology, particularly therapies targeting glioblastoma multiforme (GBM) and other aggressive brain cancers. Despite decades of research an
- SECSEC Form SC TO-C filed by Nuvalent Inc.SC TO-C - Nuvalent, Inc. (0001861560) (Subject)
- SECNuvalent Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Nuvalent, Inc. (0001861560) (Filer)
- INSIDERChief Financial Officer Balcom Alexandra exercised 11,430 shares at a strike of $6.89 and sold $1,128,080 worth of shares (11,430 units at $98.69) as part of a pre-agreed trading plan (SEC Form 4)4 - Nuvalent, Inc. (0001861560) (Issuer)
- INSIDERChief Development Officer Noci Darlene exercised 5,500 shares at a strike of $27.85 and sold $592,923 worth of shares (5,500 units at $107.80) as part of a pre-agreed trading plan (SEC Form 4)4 - Nuvalent, Inc. (0001861560) (Issuer)
- INSIDERChief Legal Officer Miller Deborah Ann exercised 5,500 shares at a strike of $6.89 and sold $593,101 worth of shares (5,500 units at $107.84) as part of a pre-agreed trading plan (SEC Form 4)4 - Nuvalent, Inc. (0001861560) (Issuer)
- PRNuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLCNew Drug Application for neladalkib in TKI pre-treated advanced ALK-positive NSCLC accepted for filing with Priority Review by the FDA with PDUFA target action date of November 27, 2026Veteran biopharmaceutical executive, Georg Pirmin Meyer, M.D., joins as Chief International Officer to lead Nuvalent's global expansion strategyCAMBRIDGE, Mass., May 27, 2026 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the acceptance of its New Drug Application (NDA) for neladalkib for filing by the U.S. Food and Drug Administration (FDA). The FDA has gra
- ANALYSTBernstein initiated coverage on Nuvalent with a new price targetBernstein initiated coverage of Nuvalent with a rating of Outperform and set a new price target of $189.00
- PRNuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual MeetingPresentation of pivotal data for neladalkib in TKI pre-treated patients with advanced ALK-positive NSCLC from ALKOVE-1 trialTKI pre-treated data from ALKOVE-1 trial of neladalkib support recent NDA submission and ongoing investigation in Phase 3 ALKAZAR trial for TKI-naïve patients with advanced ALK-positive NSCLCFirst presentation of encouraging preliminary data for zidesamtinib in patients with advanced ROS1-positive solid tumors other than NSCLC from ARROS-1 trialCAMBRIDGE, Mass., May 21, 2026 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today highli
- SECSEC Form 10-Q filed by Nuvalent Inc.10-Q - Nuvalent, Inc. (0001861560) (Filer)
- SECNuvalent Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Nuvalent, Inc. (0001861560) (Filer)
- PRNuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial ResultsNDA submitted for neladalkib in TKI pre-treated advanced ALK-positive NSCLC NDA for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC under FDA review with PDUFA target action date of September 18, 2026Submission for potential label expansion of zidesamtinib in TKI-naïve advanced ROS1-positive NSCLC planned for the second half of 2026Strengthened leadership team with key internal promotionsCAMBRIDGE, Mass., May 7, 2026 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today outlined pipeline progress, reiterated key anticipated milestones, and rep
- INSIDERPresident and CEO Porter James Richard exercised 30,000 shares at a strike of $18.93 and sold $3,050,712 worth of shares (30,000 units at $101.69) as part of a pre-agreed trading plan (SEC Form 4)4 - Nuvalent, Inc. (0001861560) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Nuvalent Inc.SCHEDULE 13G/A - Nuvalent, Inc. (0001861560) (Subject)
- INSIDERChief Financial Officer Balcom Alexandra exercised 11,430 shares at a strike of $3.25 and sold $1,131,600 worth of shares (11,430 units at $99.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Nuvalent, Inc. (0001861560) (Issuer)
- INSIDERChief Legal Officer Miller Deborah Ann exercised 5,500 shares at a strike of $6.89 and sold $545,691 worth of shares (5,500 units at $99.22) as part of a pre-agreed trading plan (SEC Form 4)4 - Nuvalent, Inc. (0001861560) (Issuer)
- INSIDERChief Development Officer Noci Darlene exercised 5,500 shares at a strike of $27.85 and sold $547,524 worth of shares (5,500 units at $99.55) as part of a pre-agreed trading plan (SEC Form 4)4 - Nuvalent, Inc. (0001861560) (Issuer)
- PRGuardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ PlatformMulti-year global collaboration will leverage Guardant's tissue and liquid biopsy portfolio to support clinical development and companion diagnostic strategies Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced a multi-year strategic collaboration with Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, to support the development and potential commercialization of Nuvalent's oncology pipeline using the tissue and liquid offerings of the Guardant Infinity™ platform. The collaboration reflects the growing importance of precision diag
- SECSEC Form DEFA14A filed by Nuvalent Inc.DEFA14A - Nuvalent, Inc. (0001861560) (Filer)
- SECSEC Form DEF 14A filed by Nuvalent Inc.DEF 14A - Nuvalent, Inc. (0001861560) (Filer)
- PRNuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual MeetingCompany to also present preliminary data for zidesamtinib in advanced ROS1-positive solid tumors outside of NSCLC from the global ARROS-1 trial CAMBRIDGE, Mass., April 21, 2026 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that pivotal data for neladalkib, an investigational ALK-selective inhibitor, in TKI pre-treated patients with advanced ALK-positive non-small cell lung cancer (NSCLC) from the global ALKOVE-1 Phase 1/2 clinical trial, in addition to preliminary data for TKI-naïve patients, will be presented during an oral presentation
- PRNew Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026Zidesamtinib demonstrated meaningful clinical activity in subset of TKI pre-treated ROS1-positive NSCLC patients from ARROS-1 trial previously treated with repotrectinib or taletrectinib, including in those with CNS disease or ROS1 resistance mutationsPreclinical data support differentiated brain penetrance and intracranial activity as compared to repotrectinib and taletrectinibCAMBRIDGE, Mass., April 17, 2026 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced new clinical and preclinical data for zidesamtinib, an investigational ROS1-selectiv
- INSIDERSEC Form 4 filed by Pelish Henry E.4 - Nuvalent, Inc. (0001861560) (Issuer)
NUVL FAQ
7 questionsWhat does Nuvalent Inc. do?
Nuvalent, Inc., a preclinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor, designed to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors; and NVL-655, a brain-penetrant ALK-selective inhibitor, designed to inhibit ALK fusions that express the normal ALK kinase domain without any drug-resistant mutations and...Where does NUVL stock trade?
Nuvalent Inc. (NUVL) is listed on NASDAQ.What sector and industry is NUVL in?
Nuvalent Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Nuvalent Inc. go public?
Nuvalent Inc. (NUVL) completed its IPO in 2021.What are analysts saying about NUVL?
Nuvalent Inc. has had 8 recent analyst actions on file. The most recent action was from Bernstein: Outperform on 2026-05-22.What companies are similar to NUVL?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare NUVL side-by-side with any of them on Quantisnow.How can I track NUVL on Quantisnow?
Quantisnow aggregates Nuvalent Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NUVL to receive live email and push alerts on every new disclosure.